Your Right to a Yaz Lawsuit, Yasmin Lawsuit, or Ocella Lawsuit

Friday August 22, 2014

Thousands of lawsuits have already been filed against the manufacturers of Yaz, Yasmin, and Ocella. These popular birth control pills were part of a false and misleading advertising campaign, and have been linked to serious health risks above and beyond those posed by other pills on the market. Yaz, Yasmin, and Ocella are the only oral contraceptives to use a new type of progestin called drospirenone, which has been shown to dangerously increase the risk of blood clots.

If you or a loved one experienced a stroke, pulmonary embolism (PE), deep vein thrombosis (DVT), blood clots, or another adverse health condition after taking these pills, you may have significant legal rights. To find out now if you have grounds to file a Yaz lawsuit, Yasmin lawsuit, or Ocella lawsuit, call us at (888) 824-5105 or send a message using our brief online form.

Legal Basis for Filing Yaz lawsuits, Yasmin lawsuits, and Ocella lawsuits

Yaz, manufactured by Bayer, is the most popular birth control pill in the United States. In 2008, sales of Yaz totaled $616 million and captured 18 percent of the U.S. market share, while sales of its predecessor, Yasmin, totaled $383 million and claimed 11 percent of the U.S. market share. In 2010, Bayer's contraceptives generated $1.58 billion in sales.

This popularity, however, was built on a false and deceptive marketing campaign by the drug's manufacturer. We now know that Yaz, its precursor Yasmin, and generic forms Ocella and Gianvi, have been linked to serious adverse health effects. Evidence shows that the manufacturer failed to warn patients and their doctors of these known risks while continuing to market the drugs as safe and effective.

Yaz Lawsuit Alleges False Advertising and Failure to Warn Consumers

In July of 2003, the United States Food and Drug Administration (FDA) reprimanded Berlex Laboritories, later acquired by Bayer, over its marketing of Yasmin. The FDA warned Berlex that its TV advertisment of Yasmin was false and misleading, and raised significant public health and safety concerns. Specifically, the FDA found that the Yasmin ads made false claims regarding the efficacy of the drug, its safety, and its superiority over other pills.

In October of 2008, the FDA again warned that two of Bayer's TV advertisments for Yaz were false and misleading. The Yaz ads similarly overstated the efficacy of the drug and downplayed the increased risks posed by drospirenone. In addition, the Yaz ads encouraged use of the drug to reduce symptoms of PMS, such as irritability, bloating, headaches, moodiness, and fatigue. Bayer made these claims even though the FDA-approved label for the drug specifically stated, "YAZ has not been evaluated for the treatment of premenstrual syndrome (PMS)."

In March of 2009, the FDA sent a third warning letter to Bayer. This time, Bayer's advertisement failed to warn of any risks associated with Yaz. The FDA found this omission "particularly concerning" since the FDA previously required that the labeling for Yaz contain a Boxed Warning - the strongest safety warning required by the FDA. The advertisement also implied that Yaz could benefit all patients with acne, even though the drug was only approved for the treatment of moderate acne vulgaris in a limited patient population.

Yaz Lawsuit Alleges that Truth Came Too Late for Most Victims

In February of 2009, before its latest violation, Bayer began running a corrective ad campaign to clarify the false and misleading statements of its previous advertisements. These corrective ads were required as part of a legal settlement with the FDA and the attorneys general of 27 states. However, an untold number of women have already been injured. From 2004 through 2008 alone, the FDA received over 50 reports of death among users of Yaz and Yasmin. Cardiac complications, blood-clots, stroke, and elevated potassium levels were reported in the fatal cases, which included victims as young as 17 years of age.

In April 2012, the FDA analyzed mounting evidence of Yaz blood clots and required that new safety warnings be included in the product label for all pills containing drospirenone, such as Yaz, Yasmin, and Ocella. Unfortunately, this updated safety information came too late for thousands of women already injured by Yaz blood clots, stroke, pulmonary embolism, and deep vein thrombosis. It remains to be seen whether the new safety label will have any effect in preventing future injuries.

Choose an Experienced Law Firm to Pursue Your Yaz Lawsuit or Settlement

Our law firm has extensive experience in negotiating settlements for the victims of defective drugs and medical devices. We encourage all individuals with a potential Yaz lawsuit, Yasmin lawsuit, or Ocella lawsuit to speak with a qualified Yaz lawyer in a timely manner to ensure their legal rights do not expire.

Free Case Evaluation

Our expert attorneys are standing by





By sending, I consent to the Privacy Policy & Disclaimer.